Otsuka Pharmaceutical Development & Commercialization, Inc. To Present Scientific Data At American Psychiatric Association Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced the presentation of seven posters highlighting research and data around Otsuka’s portfolio of CNS products, including: aripiprazole for extended-release injectable suspension, brexpiprazole and the combination product of oral aripiprazole with an embedded Proteus ingestible sensor in a single tablet. The posters will be presented during the upcoming American Psychiatric Association (APA) annual meeting in Atlanta, May 14-18.